scispace - formally typeset
Search or ask a question
Author

David Wrobel

Bio: David Wrobel is an academic researcher from Harvard University. The author has contributed to research in topics: Controlled vocabulary & Metadata standard. The author has an hindex of 4, co-authored 4 publications receiving 868 citations.

Papers
More filters
Journal ArticleDOI
TL;DR: This work examines the similarities and differences between RNAi and small-molecule screens, highlighting particular characteristics of RNAi screen data that must be addressed during analysis and provides guidance on selection of analysis techniques in the context of a sample workflow.
Abstract: RNA interference (RNAi) has become a powerful technique for reverse genetics and drug discovery, and in both of these areas large-scale high-throughput RNAi screens are commonly performed. The statistical techniques used to analyze these screens are frequently borrowed directly from small-molecule screening; however, small-molecule and RNAi data characteristics differ in meaningful ways. We examine the similarities and differences between RNAi and small-molecule screens, highlighting particular characteristics of RNAi screen data that must be addressed during analysis. Additionally, we provide guidance on selection of analysis techniques in the context of a sample workflow.

583 citations

Journal ArticleDOI
Alexandra B Keenan1, Sherry L. Jenkins1, Kathleen M. Jagodnik1, Simon Koplev1, Edward He1, Denis Torre1, Zichen Wang1, Anders B. Dohlman1, Moshe C. Silverstein1, Alexander Lachmann1, Maxim V. Kuleshov1, Avi Ma'ayan1, Vasileios Stathias2, Raymond Terryn2, Daniel J. Cooper2, Michele Forlin2, Amar Koleti2, Dusica Vidovic2, Caty Chung2, Stephan C. Schürer2, Jouzas Vasiliauskas3, Marcin Pilarczyk3, Behrouz Shamsaei3, Mehdi Fazel3, Yan Ren3, Wen Niu3, Nicholas A. Clark3, Shana White3, Naim Al Mahi3, Lixia Zhang3, Michal Kouril3, John F. Reichard3, Siva Sivaganesan3, Mario Medvedovic3, Jaroslaw Meller3, Rick J. Koch1, Marc R. Birtwistle1, Ravi Iyengar1, Eric A. Sobie1, Evren U. Azeloglu1, Julia A. Kaye4, Jeannette Osterloh4, Kelly Haston4, Jaslin Kalra4, Steve Finkbiener4, Jonathan Z. Li5, Pamela Milani5, Miriam Adam5, Renan Escalante-Chong5, Karen Sachs5, Alexander LeNail5, Divya Ramamoorthy5, Ernest Fraenkel5, Gavin Daigle6, Uzma Hussain6, Alyssa Coye6, Jeffrey D. Rothstein6, Dhruv Sareen7, Loren Ornelas7, Maria G. Banuelos7, Berhan Mandefro7, Ritchie Ho7, Clive N. Svendsen7, Ryan G. Lim8, Jennifer Stocksdale8, Malcolm Casale8, Terri G. Thompson8, Jie Wu8, Leslie M. Thompson8, Victoria Dardov7, Vidya Venkatraman7, Andrea Matlock7, Jennifer E. Van Eyk7, Jacob D. Jaffe9, Malvina Papanastasiou9, Aravind Subramanian9, Todd R. Golub, Sean D. Erickson10, Mohammad Fallahi-Sichani10, Marc Hafner10, Nathanael S. Gray10, Jia-Ren Lin10, Caitlin E. Mills10, Jeremy L. Muhlich10, Mario Niepel10, Caroline E. Shamu10, Elizabeth H. Williams10, David Wrobel10, Peter K. Sorger10, Laura M. Heiser11, Joe W. Gray11, James E. Korkola11, Gordon B. Mills12, Mark A. LaBarge13, Mark A. LaBarge14, Heidi S. Feiler11, Mark A. Dane11, Elmar Bucher11, Michel Nederlof11, Damir Sudar11, Sean M. Gross11, David Kilburn11, Rebecca Smith11, Kaylyn Devlin11, Ron Margolis, Leslie Derr, Albert Lee, Ajay Pillai 
TL;DR: The LINCS program focuses on cellular physiology shared among tissues and cell types relevant to an array of diseases, including cancer, heart disease, and neurodegenerative disorders.
Abstract: The Library of Integrated Network-Based Cellular Signatures (LINCS) is an NIH Common Fund program that catalogs how human cells globally respond to chemical, genetic, and disease perturbations. Resources generated by LINCS include experimental and computational methods, visualization tools, molecular and imaging data, and signatures. By assembling an integrated picture of the range of responses of human cells exposed to many perturbations, the LINCS program aims to better understand human disease and to advance the development of new therapies. Perturbations under study include drugs, genetic perturbations, tissue micro-environments, antibodies, and disease-causing mutations. Responses to perturbations are measured by transcript profiling, mass spectrometry, cell imaging, and biochemical methods, among other assays. The LINCS program focuses on cellular physiology shared among tissues and cell types relevant to an array of diseases, including cancer, heart disease, and neurodegenerative disorders. This Perspective describes LINCS technologies, datasets, tools, and approaches to data accessibility and reusability.

300 citations

Journal ArticleDOI
TL;DR: In this paper, the authors present metadata specifications for the most important molecular and cellular components and recommend them for adoption beyond the National Institutes of Health Library of Integrated Network-based Cellular Signatures (LINCS) program.
Abstract: The National Institutes of Health Library of Integrated Network-based Cellular Signatures (LINCS) program is generating extensive multidimensional data sets, including biochemical, genome-wide transcriptional, and phenotypic cellular response signatures to a variety of small-molecule and genetic perturbations with the goal of creating a sustainable, widely applicable, and readily accessible systems biology knowledge resource. Integration and analysis of diverse LINCS data sets depend on the availability of sufficient metadata to describe the assays and screening results and on their syntactic, structural, and semantic consistency. Here we report metadata specifications for the most important molecular and cellular components and recommend them for adoption beyond the LINCS project. We focus on the minimum required information to model LINCS assays and results based on a number of use cases, and we recommend controlled terminologies and ontologies to annotate assays with syntactic consistency and semantic integrity. We also report specifications for a simple annotation format (SAF) to describe assays and screening results based on our metadata specifications with explicit controlled vocabularies. SAF specifically serves to programmatically access and exchange LINCS data as a prerequisite for a distributed information management infrastructure. We applied the metadata specifications to annotate large numbers of LINCS cell lines, proteins, and small molecules. The resources generated and presented here are freely available.

76 citations

Journal ArticleDOI
TL;DR: The informatics and administrative needs of an HTS facility may be best managed by a single, integrated, web-accessible application such as Screensaver, which has proven useful in meeting the requirements of the ICCB-Longwood/NSRB Screening Facility at Harvard Medical School.
Abstract: Shared-usage high throughput screening (HTS) facilities are becoming more common in academe as large-scale small molecule and genome-scale RNAi screening strategies are adopted for basic research purposes. These shared facilities require a unique informatics infrastructure that must not only provide access to and analysis of screening data, but must also manage the administrative and technical challenges associated with conducting numerous, interleaved screening efforts run by multiple independent research groups. We have developed Screensaver, a free, open source, web-based lab information management system (LIMS), to address the informatics needs of our small molecule and RNAi screening facility. Screensaver supports the storage and comparison of screening data sets, as well as the management of information about screens, screeners, libraries, and laboratory work requests. To our knowledge, Screensaver is one of the first applications to support the storage and analysis of data from both genome-scale RNAi screening projects and small molecule screening projects. The informatics and administrative needs of an HTS facility may be best managed by a single, integrated, web-accessible application such as Screensaver. Screensaver has proven useful in meeting the requirements of the ICCB-Longwood/NSRB Screening Facility at Harvard Medical School, and has provided similar benefits to other HTS facilities.

31 citations

Journal ArticleDOI
26 May 2022-eLife
TL;DR: Identification of the antifibrotic effects of NCMC and the elucidation of pathways by which NCMC inhibits fibrosis provide new tools and therapeutic targets that could potentially be utilized to combat the development and progression of liver fibrosis.
Abstract: Chronic liver injury causes fibrosis, characterized by the formation of scar tissue resulting from excessive accumulation of extracellular matrix (ECM) proteins. Hepatic stellate cell (HSC) myofibroblasts are the primary cell type responsible for liver fibrosis, yet there are currently no therapies directed at inhibiting the activity of HSC myofibroblasts. To search for potential anti-fibrotic compounds, we performed a high-throughput compound screen in primary human HSC myofibroblasts and identified 19 small molecules that induce HSC inactivation, including the polyether ionophore nanchangmycin (NCMC). NCMC induces lipid re-accumulation while reducing collagen expression, deposition of collagen in the extracellular matrix, cell proliferation, and migration. We find that NCMC increases cytosolic Ca2+ and reduces the phosphorylated protein levels of FYN, PTK2 (FAK), MAPK1/3 (ERK2/1), HSPB1 (HSP27), and STAT5B. Further, depletion of each of these kinases suppress COL1A1 expression. These studies reveal a signaling network triggered by NCMC to inactivate HSC myofibroblasts and reduce expression of proteins that compose the fibrotic scar. Identification of the antifibrotic effects of NCMC and the elucidation of pathways by which NCMC inhibits fibrosis provide new tools and therapeutic targets that could potentially be utilized to combat the development and progression of liver fibrosis.

1 citations


Cited by
More filters
Journal ArticleDOI
TL;DR: ChEMBL is an open large-scale bioactivity database that includes the annotation of assays and targets using ontologies, the inclusion of targets and indications for clinical candidates, addition of metabolic pathways for drugs and calculation of structural alerts.
Abstract: ChEMBL is an open large-scale bioactivity database (https://www.ebi.ac.uk/chembl), previously described in the 2012 and 2014 Nucleic Acids Research Database Issues. Since then, alongside the continued extraction of data from the medicinal chemistry literature, new sources of bioactivity data have also been added to the database. These include: deposited data sets from neglected disease screening; crop protection data; drug metabolism and disposition data and bioactivity data from patents. A number of improvements and new features have also been incorporated. These include the annotation of assays and targets using ontologies, the inclusion of targets and indications for clinical candidates, addition of metabolic pathways for drugs and calculation of structural alerts. The ChEMBL data can be accessed via a web-interface, RDF distribution, data downloads and RESTful web-services.

1,601 citations

Journal ArticleDOI
TL;DR: A new dedicated aspect of BioGRID annotates genome-wide CRISPR/Cas9-based screens that report gene–phenotype and gene–gene relationships, and captures chemical interaction data, including chemical–protein interactions for human drug targets drawn from the DrugBank database and manually curated bioactive compounds reported in the literature.
Abstract: The Biological General Repository for Interaction Datasets (BioGRID: https://thebiogrid.org) is an open access database dedicated to the curation and archival storage of protein, genetic and chemical interactions for all major model organism species and humans. As of September 2018 (build 3.4.164), BioGRID contains records for 1 598 688 biological interactions manually annotated from 55 809 publications for 71 species, as classified by an updated set of controlled vocabularies for experimental detection methods. BioGRID also houses records for >700 000 post-translational modification sites. BioGRID now captures chemical interaction data, including chemical-protein interactions for human drug targets drawn from the DrugBank database and manually curated bioactive compounds reported in the literature. A new dedicated aspect of BioGRID annotates genome-wide CRISPR/Cas9-based screens that report gene-phenotype and gene-gene relationships. An extension of the BioGRID resource called the Open Repository for CRISPR Screens (ORCS) database (https://orcs.thebiogrid.org) currently contains over 500 genome-wide screens carried out in human or mouse cell lines. All data in BioGRID is made freely available without restriction, is directly downloadable in standard formats and can be readily incorporated into existing applications via our web service platforms. BioGRID data are also freely distributed through partner model organism databases and meta-databases.

1,046 citations

Journal ArticleDOI
TL;DR: A review of the latest applications of CRISPR-Cas9 in mammalian functional genomics screens is presented in this article, which covers related genome-scale applications of Cas9 for either gene knockout or transcriptional modulation.
Abstract: CRISPR–Cas9 has been adopted as a powerful genome-editing technology in various species. By generating libraries of thousands of guide RNAs — which direct the Cas9 nuclease to chosen genomic loci — high-throughput genetic perturbations are now possible. This Review discusses the latest applications of CRISPR–Cas9 in mammalian functional genomics screens. It covers related genome-scale applications of Cas9 for either gene knockout or transcriptional modulation, and provides comparisons with complementary RNA interference (RNAi)-based approaches.

980 citations

Journal ArticleDOI
TL;DR: The suitability of spheroids as an in vitro platform for testing drug delivery systems is examined and the assay techniques required for the characterization of drug delivery and efficacy in sp Heroids are discussed.

936 citations

Journal ArticleDOI
24 Apr 2012-ACS Nano
TL;DR: It is demonstrated that it is possible to predict the toxicity of a large series of MOx nanoparticles in the lung premised on semiconductor properties and an integrated in vitro/in vivo hazard ranking model premisedon oxidative stress.
Abstract: We demonstrate for 24 metal oxide (MOx) nanoparticles that it is possible to use conduction band energy levels to delineate their toxicological potential at cellular and whole animal levels. Among the materials, the overlap of conduction band energy (Ec) levels with the cellular redox potential (−4.12 to −4.84 eV) was strongly correlated to the ability of Co3O4, Cr2O3, Ni2O3, Mn2O3, and CoO nanoparticles to induce oxygen radicals, oxidative stress, and inflammation. This outcome is premised on permissible electron transfers from the biological redox couples that maintain the cellular redox equilibrium to the conduction band of the semiconductor particles. Both single-parameter cytotoxic as well as multi-parameter oxidative stress assays in cells showed excellent correlation to the generation of acute neutrophilic inflammation and cytokine responses in the lungs of C57 BL/6 mice. Co3O4, Ni2O3, Mn2O3, and CoO nanoparticles could also oxidize cytochrome c as a representative redox couple involved in redox ho...

702 citations